Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial

Shi, Zhongxing; Wang, Dongqing; Kang, Tanrong; Yi, Ru; Cui, Liming; Jiang, Huijie

doi:10.2478/raon-2023-0001

Abstract

Background

This trial aimed to compare the outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres^® microspheres (CSM) and conventional transarterial chemoembolization cTACE in the treatment of patients with unresectable hepatocellular carcinoma (HCC).

Patients and methods

A total of 90 patients were divided into DEB-TACE group (n = 45) and cTACE group (n = 45). The treatment response, overall survival (OS), progression-free survival (PFS), and the safety were compared between the two groups.

Results

The objective response rate (ORR) in the DEB-TACE group was significantly higher than that in cTACE group at 1, 3, and 6 months of follow-up (P = 0.031, P = 0.003, P = 0.002). The complete response (CR) in DEB-TACE group was significantly higher than that in cTACE group at 3 months (P = 0.036). Survival analysis revealed that, DEB-TACE group had better survival benefits than cTACE group (median OS: 534 days vs. 367 days, P = 0.027; median PFS: 352 days vs. 278 days P = 0.004). The degree of liver function injury was more serious in DEB-TACE group at 1 week, but was similar between the two groups at 1 month. DEB-TACE with CSM caused a high incidence of fever and a severe abdominal pain (P = 0.031, P = 0.037).

Conclusions

DEB-TACE with CSM showed better treatment response and survival benefits than cTACE group. Although a transient more severe liver damage, high incidence of fever and a severe abdominal pain occurred in the DEB-TACE group, it could be resolved through symptomatic treatment.

References

Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, et al. Comprehensive predictive factors for CalliSpheres^® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol 2021; 45: 101460. doi: 10.1016/j. clinre.2020.05.008
Open DOI Search in Google Scholar Back to article
Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018; 67: 401-21. doi: 10.1002/hep.29487
Open DOI Search in Google Scholar Back to article
Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016; 36: 166-76. doi: 10.1111/liv.12965
Open DOI Search in Google Scholar Back to article
Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017; 19: 40. doi: 10.1007/s11912-017-0597-2
Open DOI Search in Google Scholar Back to article
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-66. doi: 10.1111/liv.12818
Open DOI Search in Google Scholar Back to article
de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 2016; 39: 334-43. doi: 10.1007/s00270-015-1208-y
Open DOI Search in Google Scholar Back to article
Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres^® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres^® Transarterial Chemoembolization in Liver Cancer (CTILC) study. Oncol Res 2020; 28: 75-94. doi: 10.3727/096504019x15662966719585
Open DOI Search in Google Scholar Back to article
Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, et al. The comprehensive analysis of efficacy and safety of CalliSpheres^® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study. Oncol Res 2020; 28: 249-71. doi: 10.3727/096504019x15766663541105
Open DOI Search in Google Scholar Back to article
Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis. Clin Res Hepatol Gas 2022; 46: 101893. doi: 10.1016/j. clinre.2022.101893
Open DOI Search in Google Scholar Back to article
Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol 2018; 16: 69. doi: 10.1186/s12957-018-1368-8
Open DOI Search in Google Scholar Back to article
Ma Y, Zhao C, Zhao H, Li H, Chen C, Xiang H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres^® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res 2019; 11: 7456-70. PMID: 31934293
Search in Google Scholar Back to article
Duan XH, Ju SG, Han XW, Ren JZ, Li FY, Chen PF, et al. Arsenic trioxideeluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharmaco 2020; 24: 1468-80. doi: 10.26355/eurrev_202002_20206
Open DOI Search in Google Scholar Back to article
Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat 2019; 18: 1533033819830751. doi: 10.1177/1533033819830751
Open DOI Search in Google Scholar Back to article
Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, et al. Comparison of chemoembolization with CalliSpheres^® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res 2020; 12: 941-56. doi: 10.2147/cmar.S187203
Open DOI Search in Google Scholar Back to article
Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, et al. Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: Multicenter study. AJR Am J Roentgenol 2021; 217: 933-43. doi: 10.2214/ajr.20.24708
Open DOI Search in Google Scholar Back to article
Zhang S, Huang C, Li Z, Yang Y, Bao T, Chen H, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers. Drug Deliv 2017; 24: 1011-7. doi: 10.1080/10717544.2017.1344336
Open DOI Search in Google Scholar Back to article
Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol 2018; 24: 161-9. doi: 10.3748/wjg.v24.i2.161
Open DOI Search in Google Scholar Back to article
Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28-36. doi: 10.1016/j.ctrv.2018.11.002
Open DOI Search in Google Scholar Back to article
Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma 2019; 6: 105-17. doi: 10.2147/jhc.S168682
Open DOI Search in Google Scholar Back to article
Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres^® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis. Front Oncol 2021; 11: 576232. doi: 10.3389/fonc.2021.576232
Open DOI Search in Google Scholar Back to article
Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018; 18: 124. doi: 10.1186/s12876-018-0848-1
Open DOI Search in Google Scholar Back to article
Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50. doi: 10.1016/j.jhep.2012.07.017
Open DOI Search in Google Scholar Back to article
Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gadtroen Hepatol 2016; 31: 645-53. doi: 10.1111/jgh.13147
Open DOI Search in Google Scholar Back to article
Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465. doi: 10.1186/s12885-015-1480-x
Open DOI Search in Google Scholar Back to article
Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2014; 20: 17206-17. doi: 10.3748/wjg.v20.i45.17206
Open DOI Search in Google Scholar Back to article